Active substanceInosineInosine
Similar drugsTo uncover
  • Inosie-F®
    solution in / in 
    Europharm (UK) Co., Ltd.     United Kingdom
  • Inosine
    solution in / in 
    Ama Pharm, OOO     China
  • Inozin-Eskom
    solution in / in 
    ESKOM NPK, OAO     Russia
  • Riboxin
    solution in / in 
    ATOLL, LLC     Russia
  • Riboxin
    solution in / in 
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
    VALENTA PHARM, PAO     Russia
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
    IRBITSK HFZ, OJSC     Russia
  • Riboxin
    pills inwards 
  • Riboxin
    solution in / in 
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
  • Riboxin
    pills inwards 
    MAKSFARM, OJSC     Russia
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
    BINNOFARM, CJSC     Russia
  • Riboxin
    pills inwards 
  • Riboxin
    pills inwards 
    OZONE, LLC     Russia
  • Riboxin
    pills inwards 
    BIOSINTEZ, PAO     Russia
  • Riboxin
    pills inwards 
  • Riboxin
    pills inwards 
    DALHIMFARM, OJSC     Russia
  • Riboxin
    solution in / in 
    BIOSINTEZ, PAO     Russia
  • Riboxin
    pills inwards 
    NORTH STAR, CJSC     Russia
  • Riboxin
    capsules inwards 
    MINSKINTERKAPS, UP     Republic of Belarus
  • Riboxin
    solution in / in 
    VEROPHARM SA     Russia
  • Riboxin
    pills inwards 
    Mapichem AG     Switzerland
  • Riboxin
    solution in / in 
    Mapichem AG     Switzerland
  • Riboxin
    solution in / in 
    DALHIMFARM, OJSC     Russia
  • Riboxin
    solution in / in 
    ELLARA, LTD.     Russia
  • Riboxin
    solution in / in 
    GROTEKS, LLC     Russia
  • Riboxin
    solution in / in 
    VELFARM, LLC     Republic of San Marino
  • Riboxin of Avexime
    pills inwards 
  • Riboxin Beefus
    solution in / in 
    UPDATE OF PFC, CJSC     Russia
  • Riboxin-Vial
    solution in / in 
    VIAL, LLC     Russia
  • Riboxin-LexT
    pills inwards 
  • Riboxin-Ferein
    pills inwards 
    BRYNTSALOV-A, CJSC     Russia
  • ASFARMA, LLC     Russia
  • Dosage form: & nbspfilm-coated tablets
    Composition:

    1 tablet contains:

    active substance: inosine (riboxin) 200 mg;

    Excipients: lactose monohydrate 27.0 mg, microcrystalline cellulose 34.0 mg, copovidone 6.3 mg, calcium stearate 2.7 mg;

    shell: Opadry II (series 85) 8.0 mg: polyvinyl alcohol partially hydrolysed 40.00%, macrogol 3350 20.20%, titanium dioxide E 171 8.45%, talc 14.80%, aluminum lignol based on indigo carmine E 132 0, 01%, lacquer aluminum based on the dye sunset yellow E 110 0.15%, lacquer aluminum based on the dye quinoline yellow E 104 - 16.39%.

    Description:

    Round, biconvex tablets, covered with a film membrane; On the cross-section, two layers are visible: the shell is yellow and the core is white or almost white.

    Pharmacotherapeutic group:metabolic
    ATX: & nbsp

    C.01.E.B   Other drugs for the treatment of heart disease

    Pharmacodynamics:

    Refers to a group of drugs that regulate metabolic processes. Purine derivative (nucleoside), the precursor of adenosine triphosphate (ATP). Has metabolic, antihypoxic and antiarrhythmic action.

    Activates the metabolism of pyruvic acid to ensure a normal process of tissue respiration, and also promotes the activation of xanthine dehydrogenase. Stimulates the synthesis of nucleotides, enhances the activity of certain enzymes of the Krebs cycle. Penetrating into cells, increases energy metabolism,has a positive effect on the processes of metabolism in the myocardium, increases the strength of the heart contractions and promotes more complete relaxation of the myocardium in diastole, as a result of which the shock volume of blood (UOK) increases.

    Increases the energy balance of the myocardium, improves coronary circulation, prevents the consequences of intraoperative kidney ischemia. It takes a direct part in the exchange of glucose and promotes the activation of metabolism in conditions of hypoxia and in the absence of ATP.

    Reduces platelet aggregation, activates the regeneration of tissues (especially the myocardium and the mucous membrane of the gastrointestinal tract (GIT).

    Pharmacokinetics:

    It is well absorbed in the digestive tract.

    Metabolised in the liver with the formation of glucuronic acid and its subsequent oxidation. In a small amount is excreted by the kidneys.

    Indications:

    In the complex therapy of coronary heart disease, after myocardial infarction, heart rhythm disorders due to the use of cardiac glycosides.

    As part of complex therapy for hepatitis, cirrhosis, fatty liver disease caused by alcohol or drugs and urocoppororphy.

    Contraindications:

    Hypersensitivity to inosine and other components of the drug, gout, hyperuricemia, pregnancy, the period of breastfeeding, age under 18 years (efficacy and safety not established), lactose intolerance, lactase deficiency, glucose-galactose malabsorption.

    Carefully:

    Renal failure.

    Pregnancy and lactation:

    The use of the drug during pregnancy is contraindicated. If it is necessary to use the drug during lactation, breastfeeding should be stopped.

    Dosing and Administration:

    Riboxin is prescribed inside before meals.

    The daily dose for oral administration is 600 mg-2.4 g. In the first days of treatment, the daily dose is 600-800 mg (200 mg 3-4 times a day). In case of good tolerability, the daily dose is increased (2-3 days) to 1.2 g (400 mg 3 times a day), if necessary - up to 2.4 g per day.

    The duration of the course is from 4 weeks to 1.5-3 months.

    With urocoppororphy, the daily dose is 800 mg (200 mg 4 times a day).

    The drug is taken daily for 1-3 months.

    Side effects:

    Allergic reactions are possible in the form of hives, itchy skin, skin hyperemia (drug withdrawal is required).

    Rarely in the treatment with Riboxin, the concentration of uric acid in the blood increases, with prolonged use, an exacerbation of gout is possible.

    Overdose:

    There have been no cases of overdose to date.

    Interaction:

    When used as part of complex therapy inosine improves the effectiveness of antiarrhythmic, antianginal and inotropic drugs.

    Immunosuppressants (immunoglobulin antithymocyte, ciclosporin, gamma-D-glutamyl-D-tryptophan and others) with simultaneous use reduce the effectiveness of inosine.

    Clinically significant interaction of inosine with drugs of other groups is not described.

    Special instructions:

    Riboxin is not used for emergency correction of cardiac disorders.

    During the treatment with Riboxin, the concentration of uric acid in the blood and urine should be monitored.

    Effect on the ability to drive transp. cf. and fur:The drug does not affect the performance of potentially hazardous activities requiring special attention and quick reactions (driving and other vehicles, working with moving mechanisms, dispatcher and operator work, etc.).
    Form release / dosage:

    Tablets, film-coated, 200 mg.

    Packaging:

    For 10 tablets in a contour mesh box made of polyvinylchloride film and aluminum foil printed lacquered.

    5 contour mesh packages together with instructions for use in a pack of cardboard.
    Storage conditions:

    In the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:P N000096 / 01
    Date of registration:05.10.2011
    The owner of the registration certificate:VALENTA PHARM, PAO VALENTA PHARM, PAO Russia
    Manufacturer: & nbsp
    Representation: & nbspVALENTA PHARM, PAO VALENTA PHARM, PAO Russia
    Information update date: & nbsp22.10.2015
    Illustrated instructions
      Instructions
      Up